SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Goodwin FK, Jamison KR. Manic-Depressive Illness. Oxford University Press, New York, 1990.
  • 2
    Taylor MA, Abrams R. Acute mania. Clinical and genetic study of responders and nonresponders to treatments. Arch. Gen. Psychiatry 1975; 32: 863865.
  • 3
    Maj M, Pirozzi R, Magliano L. Late non-response to lithium prophylaxis in bipolar patients: Prevalence and predictors. J. Affect. Disord. 1996; 39: 3942.
  • 4
    Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am. J. Psychiatry 1999; 156: 12641266.
  • 5
    Maj M, Pirozzi R, Starace F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. J. Affect. Disord. 1989; 17: 237241.
  • 6
    Mendlewicz J, Fieve RR, Stallone F. Relationship between the effectiveness of lithium therapy and family history. Am. J. Psychiatry 1973; 130: 10111013.
  • 7
    Maj M, Del Vecchio M, Starace F, Pirozzi R, Kemali D. Prediction of affective psychoses response to lithium prophylaxis. The role of socio-demographic, clinical, psychological and bioloical variables. Acta Psychiatr. Scand. 1984; 69: 3744.
  • 8
    Keller MB, Lavori PW, Coryell W, Endicott J, Mueller TI. Bipolar I. A five-year prospective follow-up. J. Nerv. Ment. Dis. 1993; 181: 238245.
  • 9
    Swann AC, Bowden CL, Morris D et al. Depression during mania. Treatment response to lithium or divalproex. Arch. Gen. Psychiatry 1997; 54: 3742.
  • 10
    Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J. Affect. Disord. 1980; 2: 279288.
  • 11
    Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch. Gen. Psychiatry 1974; 30: 229233.
  • 12
    Prien RF, Caffey EM Jr, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis. Report of the Veterans Administration and National Institute of Mental Health collaborative Study Group. Arch. Gen. Psychiatry 1974; 31: 189192.
  • 13
    O'Connell RA, Mayo JA, Flatow L et al. Outcome of bipolar disorder on long-term treatment with lithium. Br. J. Psychiatry 1991; 159: 123129.
  • 14
    Small JG, Milstein V, Malloy FW, Klapper MH, Golay SJ, Medlock CE. Topographic EEG studies of mania. Clin. Electroencephalogr. 1998; 29: 5966.
  • 15
    Small JG, Milstein V, Malloy FW, Medlock CE, Klapper MH. Clinical and quantitative EEG studies of mania. J. Affect. Disord. 1999; 53: 217224.
  • 16
    Reeves RR, Struve FA, Patrick G. Does EEG predict response to valproate versus lithium patients with mania? Ann. Clin. Psychiatry 2001; 13: 6973.
  • 17
    Ikeda A, Kato N, Kato T. Possible relationship between electroencephalogram finding and lithium response in bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002; 26: 903907.
  • 18
    Dalen P. Family history, the electroencephalogram and perinatal factors in manic conditions. Acta Psychiatr. Scand. 1965; 41: 527563.
  • 19
    Taylor MA, Abrams R. Familial and non-familial mania. J. Affect. Disord. 1980; 2: 111118.
  • 20
    Kadrmas A, Winokur G. Manic depressive illness and EEG abnormalities. J. Clin. Psychiatry 1979; 40: 306307.
  • 21
    Cook BL, Shukla S, Hoff A. EEG abnormalities in bipolar affecctive disorder. J. Affect. Disord. 1986; 11: 147149.
  • 22
    Small JG, Milstein V, Medlock CE. Clinical EEG findings in mania. Clin. Electroencephalogr. 1997; 28: 229235.
  • 23
    Bachsbaum M, Goodwin F, Murphy D, Borge G. AER in affective disorders. Am. J. Psychiatry 1971; 128: 1925.
  • 24
    Baron M, Gershon ES, Ruby V, Jonas WZ, Bachsbaum M. Lithium carbonate response in depression. Prediction by unipolar/bipolar illness, average-evoked response, catechol-O-methyl transferase, and family history. Arch. Gen. Psychiatry 1975; 32: 11071111.
  • 25
    McKnew DH, Cytryn L, Bachsbaum M et al. Lithium in children of lithium responding parents. Psychiatry Res. 1981; 4: 171180.
  • 26
    Hegerl U, Ulrich G, Muller-Oerlinghausen B. Auditory evoked potentials and response to lithium prophylaxis. Pharmacopsychiatry 1987; 20: 213216.
  • 27
    Hegerl U, Wulff H, Muller-Oerlinghausen B. Intensity dependence of auditory evoked potentials and clinical response to prophylactic lithium medication, a replication study. Psychiatry Res. 1992; 44: 181190.
  • 28
    Young AH, Hughes JH, Marsh VR, Ashton CH. Acute tryptophan depletion attenuates auditory event related potentials in bipolar disorder: A preliminary study. J. Affect. Disord. 2002; 69: 8392.
  • 29
    Debener S, Strobel A, Kurschner K et al. Is auditory evoked potential augmenting/reducing affected by acute tryptophan depletion? Biol. Psychol. 2002; 59: 121133.
  • 30
    Hegrel U, Galliant J, Juckel G. Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J. Affect. Disord. 2001; 62: 93100.
  • 31
    Mendels J, Frazer A. Intracellular lithium concentration and clinical response. Towards a membrane theory of depression. J. Psychiatr. Res. 1973; 10: 918.
  • 32
    Frazer A, Mendels J, Brunswick D et al. Erythrocyte concentrations of the lithium ion: clinical correlates and mechanisms of action. Am. J. Psychiatry 1978; 135: 10651069.
  • 33
    Cazzullo CL, Smeraldi E, Scchetti E, Bottinelli S. Intracellular lithium concentration and clinical response. Br. J. Psychiatry 1975; 126: 298300.
  • 34
    Casper RC, Pandey G, Gosenfeld L, Davis JM. Intracellular lithium and clinical response. Lancet 1976; 2: 418419.
  • 35
    Mendels J, Frazer A, Baron J et al. Intra-erythrocyte lithium ion concentration and long-term maintenance treatment. Lancet 1976; 1: 966.
  • 36
    Swann AC, Berman N, Frazer A, Koslow SH, Secunda S. Lithium distribution in mania: Plasma and red blood cell lithium, clinical state, and monoamine metabolites during lithium treatment. Psychiatry Res. 1987; 20: 112.
  • 37
    Hitzemann R, Mark C, Hirschowitz J, Garver D. RBC lithium transport in the psychoses. Biol. Psychiatry 1989; 25: 296304.
  • 38
    Harvey NS, Kay R. Compliance during lithium treatment, intra-erythrocyte lithium variability, and relapse. J. Clin. Psychopharmacol. 1991; 11: 362367.
  • 39
    Taylor R, Mallinger AG, Frank E, Rucci P, Thase ME, Kupfer DJ. Variability of erythrocyte and serum lithium levels correlates with therapist treatment adherence efforts and maintenance treatment outcome. Neuropsychopharmacology 2001; 24: 192197.
  • 40
    Rybakowski J, Chlopocka M, Kapelski Z, Henacka B, Szajnerman Z, Kasprzak K. Red blood cell lithium index in patients with affective disorders in the course of lithium prophylaxis. Int. Pharmacopsychiatry 1974; 9: 166171.
  • 41
    Zvolsky P, Dvorakova M, Vinarova E et al. Proceedings: Genetic aspects of lithium ratio in red blood cells and in plasma of manic-depressive patients. Act. Nerv. Super. (Praha) 1975; 17: 271272.
  • 42
    Knorring L, Oreland L, Perris C, Wiberg A. Evaluation of the lithium RBC/plasma ratio as a predictor of the prophylactic effect of lithium treatment in affective disorders. Pharmakopsychiatr. Neuropsychopharmakol. 1976; 9: 8184.
  • 43
    Kocsis JH, Kantor JS, Lieberman KW, Stokes PE. Lithium ratio and maintenance treatment response. J. Affect. Disord. 1982; 4: 213218.
  • 44
    Carroll BJ. Prediction of treatment outcome with lithium. Arch. Gen. Psychiatry 1979; 36: 870878.
  • 45
    Elizur A, Yeret A, Segal Z, Graff E. Lithium and electrolytes plasma/RBC ratio and paradoxical lithium neurotoxicity. Prog. Neuropsychopharmacol. Biol. Psychiatry 1982; 6: 235241.
  • 46
    Renshaw PF, Wicklund S. In vivo measurement of lithium in humans by nuclear magnetic resonance spectroscopy. Biol. Psychiatry 1988; 23: 465475.
  • 47
    Komoroski RA, Newton JEO, Walker E et al. In vivo NMR spectroscopy of lithium-7 in humans. Magn. Reson. Med. 1990; 15: 347356.
  • 48
    Gyulai L, Wicklund SW, Greenstein R. et al. Measurement of tissue lithium concentration by lithium magnetic resonance spectroscopy in patients with bipolar disorder. Biol. Psychiatry 1991; 29: 11611170.
  • 49
    Kato T, Takahashi S, Inubushi T. Brain lithium concentration by 7Li- and 1H-magnetic resonance spectroscopy in bipolar disorder. Psychiatry Res. 1992; 45: 5363.
  • 50
    Kato T, Shioiri T, Inubushi T, Takahashi S. Brain lithium concentrations measured with lithium-7 magnetic resonance spectroscopy in patients with affective disorders: Relationship to erythrocyte and serum concentrations. Biol. Psychiatry 1993; 33: 147152.
  • 51
    Sachs GS, Renshaw PF, Lafer B et al. Variability of brain lithium levels during maintenance treatment: A magnetic resonance spectroscopy study. Biol. Psychiatry 1995; 38: 422428.
  • 52
    Kato T, Inubushi T, Takahashi S. Relationship of lithium concentration in the brain measured by lithium-7 magnetic resonance spectroscopy to treatment response in mania. J. Clin. Psychopharmacol. 1994; 14: 330335.
  • 53
    Ryder LP, Nielsen LS, Svejgaard A. Association between HL-A histocompatibility antigens and non-malignant disease. Humangenetik 1974; 25: 251264.
  • 54
    Cazzullo CL, Smeraldi E, Penati G. The leukocyte antigenic system HL-A as a possible genetic marker of schizophrenia. Br. J. Psychiatry 1974; 125: 2527.
  • 55
    Shapiro RW, Bock E, Rafaelsen OJ, Ryder LP, Svejgaard A. Histocompatibility antigens and manic-depressive disorders. Arch. Gen. Psychiatry 1976; 33: 823825.
  • 56
    Shapiro RW, Ryder LP, Svejgaard A, Rafaelsen OJ. HLA antigens and manic-depressive disorders: Further evidence of an association. Psychol. Med. 1977; 7: 387396.
  • 57
    Beckman L, Perris C, Strandman E, Wahlby L. HLA antigens and affective disorders. Hum. Hered. 1978; 28: 9699.
  • 58
    Bonara P, Bellodi L, Sacchetti E, Sabbadini-Villa MG, Cazzullo CL, Zanussi C. HLA typing and affective disorders: A study in the Italian population. Neuropsychobiology 1978; 4: 344352.
  • 59
    Perris C, Strandman E, Wahlby L. HL-A antigens and the response to prophylactic lithium. Neuropsychobiology 1979; 5: 114118.
  • 60
    Del Vecchio M, Farzati B, Maj M, Minucci P, Guida L, Kemali D. Cell membrane predictors of response to lithium prophylaxis of affective disorders. Neuropsychobiology 1981; 7: 243247.
  • 61
    Maj M, Arena F, Lovero N, Pirozzi R, Kemali D. Factors associated with response to lithium prophylaxis in DSM III major depression and bipolar disorder. Pharmacopsychiatry 1985; 18: 309313.
  • 62
    Targum SD, Gershon ES, Van Eerdewegh M, Rogentine N. Human leukocyte antigen system not closely linked to or associated with bipolar manic-depressive illness. Biol. Psychiatry 1979; 14: 615636.
  • 63
    Johnson GF, Hunt GE, Robertson S, Doran TJ. A linkage study of manic-depressive disorder with HLA antigens, blood groups, serum proteins and red cell enzymes. J. Affect. Disord. 1981; 3: 4358.
  • 64
    Goldin LR, Clerget-Darpoux F, Gershon ES. Relationship of HLA to major affective disorder not supported. Psychiatry Res. 1982; 7: 2945.
  • 65
    Campbell J, Crowe RR, Goeken N, Pfohl B, Pauls D, Palmer D. Affective disorder not linked to HLA in a large bipolar kindred. J. Affect. Disord. 1984; 7: 4551.
  • 66
    Dubovsky SL, Franks RD. Intracellular calcium ions in affective disorders: A review and a hypothesis. Biol. Psychiatry 1983; 18: 781797.
  • 67
    Yamawaki S, Kagaya A, Tawara Y, Inagaki M. Intracellular calcium signaling systems in the pathophysiology of affective disorders. Life Sci. 1998; 62: 16651670.
  • 68
    Meltzer HL. Lithium mechanisms in bipolar illness and altered intracellular calcium functions. Biol. Psychiatry 1986; 21: 492510.
  • 69
    Berridge MJ. Inositol trisphosphate, calcium, lithium, and cell signaling. JAMA 1989; 262: 18341841.
  • 70
    Atack JR, Broughton HB, Pollack SJ. Inositol monophosphatase: A putative target for Li+ in the treatment of bipolar disorder. Trends Neurosci. 1995; 18: 343349.
  • 71
    Shaldubina A, Agam G, Belmaker RH. The mechanism of lithium action: State of the art, ten years later. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001; 25: 855866.
  • 72
    Emamghoreishi M, Schlichter L, Li PP et al. High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Am. J. Psychiatry 1997; 154: 976982.
  • 73
    Nemanov L, Ebstein RP, Belmaker RH, Osher Y, Agam G. Effect of bipolar disorder on lymphocyte inositol monophosphatase mRNA levels. Int. J. Neuropsychopharmcol. 1999; 2: 2529.
  • 74
    Yoon IS, Li PP, Siu KP et al. Altered IMPASE2 gene expression and calcium homeostasis in bipolar disorder. Mol. Psychiatry 2001; 6: 678683.
  • 75
    Suzuki K, Kusumi I, Sasaki Y, Koyama T. Serotonin-induced platelet intracellular calcium mobilization in various psychiatric disorders: Is it specific to bipolar disorder?. J. Affect. Disord. 2001; 64: 291296.
  • 76
    Kusumi I, Koyama T, Yamashita I. Serotonin-induced platelet intracellular calcium mobilization in depressed patients. Psychopharmacology (Berl.) 1994; 113: 322327.
  • 77
    Kusumi I, Suzuki K, Sasaki Y, Kameda K, Koyama T. Treatment response in depressed patients with enhanced Ca mobilization stimulated by serotonin. Neuropsychopharmacology 2000; 23: 690696.
  • 78
    Dewan MJ, Haldipur CV, Boucher MF, Ramachandran T, Major LF. Bipolar affective disorder II. EEG, neuropsychological, and clinical correlates of CT abnormality. Acta Psychiatr. Scand. 1988; 77: 677682.
  • 79
    Besson JA, Henderson JG, Foreman EI, Smith FW. An NMR study of lithium responding manic depressive patients. Magn. Reson. Imaging 1987; 5: 273277.
  • 80
    Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK, Menji HK. Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 12411242.
  • 81
    Sassi RB, Nicoletti M, Brambilla P et al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci. Lett. 2002; 329: 243245.
  • 82
    Moore GJ, Bebchuk JM, Hasanat K et al. Lithium increases N-acetyl-aspartate in the human brain: In vivo evidence in support of bcl-2′s neurotrophic effects? Biol. Psychiatry 2000; 48: 18.
  • 83
    Moore GJ, Bebchuk JM, Parrish JK et al. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am. J. Psychiatry 1999; 156: 19021908.
  • 84
    Davanzo P, Thomas MA, Yue K et al. Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology 2001; 24: 359369.
  • 85
    Kato T, Fujii K, Kamiya A, Kato N. White matter hyperintensity detected by magnetic resonance imaging and lithium response in bipolar disorder, a preliminary observation. Psychiatry Clin. Neurosci. 2000; 54: 117120.
  • 86
    Kato T, Inubushi T, Kato N. Prediction of lithium response by 31P-MRS in bipolar disorder. Int. J. Neuropsychopharmacol. 2000; 3: 8385.
  • 87
    Kato T, Murashita J, Kamiya A, Shioiri T, Kato N, Inubushi T. Decreased brain in tracellular pH measured by 31P-MRS in bipolar disorder: A confirmation in drug-free patients and correlation with white matter hyperintensity. Eur. Arch. Psychiatry Clin. Neurosci. 1998; 248: 301306.
  • 88
    Murashita J, Kato T, Shioiri T, Inubushi T, Kato N. Altered brain energy metabolism in lithium-resistant bipolar disorder detected by photic stimulated 31P-MR spectroscopy. Psychol. Med. 2000; 30: 107115.
  • 89
    Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 1998; 3: 508511.
  • 90
    Whale R, Quested DJ, Laver D, Harrison PJ, Cowen PJ. Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology 2000; 150: 120122.
  • 91
    Zanardi R, Serretti A, Rossini D et al. Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychiatry 2001; 50: 323330.
  • 92
    Kim DK, Lim SW, Lee S et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215219.
  • 93
    Yoshida K, Ito K, Sato K et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002; 26: 383386.
  • 94
    Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J. 2001; 1: 7177.
  • 95
    Del Zompo M, Ardau R, Palmas MA, Bocchetta A, Reina A, Piccardi MP. Lithium response: Association study with two candidate genes. Mol. Psychiatry 1999; 4 (Suppl.): S66S67.
  • 96
    Serretti A, Lilli R, Lorenzi C, Franchini L, Smeraldi E. Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. Int. J. Neuropsychopharmacol. 1998; 1: 125129.
  • 97
    Serretti A, Lilli R, Lorenzi C et al. Dopamine receptor D2 and D4 genes, GABA (A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Res. 1999; 87: 719.
  • 98
    Serretti A, Lorenzi C, Lilli R, Mandelli L, Pirovano A, Smeraldi E. Pharmacogenetics of lithium prophylaxis in mood disorders. Analysis of COMT, MAO-A, and Gbeta3 variants. Am. J. Med. Genet. 2002; 114: 370379.
  • 99
    Serretti A, Lilli R, Lorenzi C, Gasperini M, Smeraldi E. Tryptophan hydroxylase gene and resonse to lithium phropylaxis in mood disorders. J. Psychiatr. Res. 1999; 33: 371377.
  • 100
    Turecki G, Grof P, Cavazzoni P et al. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol. Psychiatry 1998; 3: 534538.
  • 101
    Lovlie R, Berle JO, Stordal E, Steen VM. The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: Re-examination of an intronic dinucleotide repeat polymorphism. Psychiatr. Genet. 2001; 11: 4143.
  • 102
    Turecki G, Grof P, Grof E et al. Mapping susceptibility genes for bipolar disorder: A pharmacogenetic approach based on excellent response to lithium. Mol. Psychiatry 2001; 6: 570578.
  • 103
    Shamir A, Ebstein RP, Nemanov L, Zohar A, Belmaker RH, Agam G. Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy. Mol. Psychiatry 1998; 3: 481482.
  • 104
    Sjoholt G, Gulbrandsen AK, Lovlie R, Berle JO, Molven A, Steen VM. A human myo-inositol monophosphatase gene (IMPA2) localized in a putative susceptibility region for bipolar disorder on chromosome 18p11.2: Genomic structure and polymorphism screening in manic-depressive patients. Mol. Psychiatry 2000; 5: 172180.
  • 105
    Yoshikawa T, Padigaru M, Karkera JD et al. Genomic structure and novel variants of myo-inositol monophosphatase 2 (IMPA2). Mol. Psychiatry 2000; 5: 165171.
  • 106
    Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 1998; 8: 259268.
  • 107
    Swayze VW II, Andreasen NC, Alliger RJ, Ehrhardt JC, Yuh WT. Structural brain abnormalities in bipolar affective disorder. Ventricular enlargement and focal signal hyperintensities. Arch. Gen. Psychiatry 1990; 47: 10541059.
  • 108
    Altshuler LL, Curran JG, Hauser P, Mintz J, Denicoff K, Post R. T2 hyperintensities in bipolar disorder: Magnetic resonance imaging comparison and literature meta-analysis. Am. J. Psychiatry 1995; 152: 11391144.